- Research article
- Open Access
- Open Peer Review
The influence of statins on the free intracellular calcium concentration in human umbilical vein endothelial cells
BMC Cardiovascular Disordersvolume 4, Article number: 4 (2004)
Statins are cholesterol-lowering drugs that are widely used to reduce the risk of cardiac infarction. Their beneficial clinical effects, however, are not restricted to their influence on cholesterol production. As several studies have shown that they have a potency of relaxing blood vessels.
We measured the effects of statins on the intracellular free calcium concentration ([Ca2+]i) in human umbilical vein endothelial cells (HUVEC) after acute application and 24-h-preincubation of statins.
Incubation of the cells for 24 h with cerivastatin or fluvastatin significantly increased the resting [Ca2+]i. For cerivastatin this effect manifested at a concentration of 1 μM. Increase of resting [Ca2+]i in the presence of cerivastatin also occurred when the nitric oxide synthase was inhibited. Transient Ca2+ release induced by histamine was not affected.
The increase of resting [Ca2+]i after incubation with cerivastatin or fluvastatin may provide an explanation for the direct effects of statins on the endothelial-dependent vasodilatation and restoration of endothelial activity in vivo.
Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (statins) are drugs widely used in the treatment of hypercholesterolaemia. A large number of clinical trials (4S, CARE, WOSCOPS) has demonstrated that treatment of patients with statins reduces the number of cardiac or cerebral ischaemic events even in the absence of further reduction in serum cholesterol levels [15, 16].
In addition to their lipid-lowering activity, statins seem to possess relevant properties that target multiple mechanisms contributing to the progression of arteriosclerosis: leucocyte adhesion, macrophage stimulation, inflammatory responses, smooth muscle cell activation, and endothelial dysfunction. In patients with moderate hypercholesterolaemia, treatment with simvastatin improved both the acetylcholine-stimulated and basal nitric oxide mediated vasodilatation measured by use of strain-gauge plethysmography within one month . Simvastatin produced relaxation of small resistance arteries of the rat through a mevalonate sensitive pathway . Moreover, it was shown that simvastatin and atorvastatin reduced the concentration of endothelin 1 (ET-1) via a decreased expression of pre-pro ET-1 mRNA in bovine aortic endothelial cells. This effect persisted after the addition of oxidized low-density lipoprotein cholesterol . Various statins inhibited superoxide anion (O2 -) formation and improved nitric oxide (NO) dependent vasodilatation through an influence on the NO/O2 - balance in the vessel wall .
In endothelial cells, after treatment with simvastatin and lovastatin an up to 3.8 fold increase of eNOS expression was measured . Other experiments have provided evidence for improved NOS mRNA stability after treatment with simvastatin . Further it was shown that pravastatin and simvastatin increased the endothelium-dependent vasorelaxation in aortic rings and also the NO production by cultured bovine aortic endothelial cells .
Although these properties of statins may be relevant for their beneficial effects on cardiovascular diseases, they do not elucidate the signal pathway of statins on acute endothelium-dependent relaxation of blood vessels. eNOS is a calmodulin-binding enzyme and is abundantly expressed in endothelial cells. An increase of the cytosolic free calcium concentration subsequent to receptor stimulation through agonists like histamine or bradykinin is the main signal for stimulation of synthesis of NO in endothelial cells.
The aim of the present study was therefore to investigate the possible role of free intracellular calcium in the pathway of statin-induced endothelium dependent relaxation. For this purpose we examined the influence of two different statins (cerivastatin and fluvastatin) on agonist-induced transients and resting levels of [Ca2+]i in cultured human endothelial cells.
Endothelial cells from human umbilical vein (HUVEC-p, Promocell, Heidelberg, Germany) were cultured in EGM-MV Bulletkit medium (BioWhittaker, Verviers, Belgium) containing 0.1% human endothelial growth factor, 0.1% hydrocortison, 5% human serum, 0.4% bovine brain extract, 0.1% gentamycin. Cultures were maintained at 37°C in a fully humidified atmosphere with 5% CO2 up to passage 6. SH-SY5Y human neuroblastoma cells (DSMZ Braunschweig, Germany) were cultured in DMEM medium containing 10% fetal calf serum (Gibco, Life Technologies, Eggenstein, Germany) in 10% CO2. Cells were detached from the culture bottles by exposure to 0.5 g/l trypsin in a Ca2+- and Mg2+-free solution for approximately 180 s and plated on gelatine-coated glass coverslips.
Changes of [Ca2+]i were measured fluorimetrically. The plated cells were loaded with Fura-2-AM (Molecular Probes, Eugene, USA) by incubating them for 40 min and 37°C at a dye concentration of 1 μM. After incubation, cells were washed 2 times with Krebs solution (see below) to remove extracellular Fura-2-AM. Fluorescence measurements were performed with a combination of a scanning monochromator and a CCD camera operated by TILLvisION software (Till Imago, T.I.L.L Photonics, Gräfelfing, Germany). The camera was mounted to an inverted microscope (Axiovert 100, Carl Zeiss, Jena, Germany) with a 40x objective (Neofluar, Carl Zeiss). Cells were exposed to alternating excitation light pules of 340 and 380 nm wavelength of each 200 ms at intervals of 2 s. Emission images were collected during these pulses. Fluorescence values were corrected for background fluorescence before starting data collection from the emission images. Per experiment up to 8 cells were analyzed simultaneously by defining corresponding areas of interest in the images. The fluorescence intensity ratio (FR), which is related to [Ca2+]i, was calculated for single cells over the whole experiment by forming the ratio of the fluorescence values at 340 and 380 nm excitation: FR = F340 / F380 .
During the measurements, cells were continuously superfused with Krebs solution containing (in mM): NaCl 140, KCl 6, CaCl2 1.5, MgCl2 1.2, HEPES 11.5, Glucose 10 and adjusted to pH 7.3 with 1 M NaOH; osmolarity was 295 mOsm. The application of all solutions was performed with an application tip located 3 mm away from the measured cells.
Cerivastatin (Bayer AG, Leverkusen, Germany) and fluvastatin (Novartis Pharma AG, Basel, Switzerland) were generously supplied by the respective companies. Cerivastatin and fluvastatin were dissolved in water . N-Omega-Nitro-L-Arginine (L-NAME) and histamine were purchased from Sigma-Aldrich Chemie (Taufkirchen, Germany).
To examine the long-term effects of statins on intracellular calcium homeostasis, cells were treated with the statins one day after seeding by adding appropriate volumes of stock solutions to the cell culture. Cells kept under the same conditions, but without statin treatment, served as control groups.
After 24 h statin incubation the cells were loaded with Fura-2-AM. FR was measured for 20 s under resting conditions, followed by an application of 10 μM histamine for 60 s and washed out for about 120 s. The mean value of FR of each cell measured over 10 s was used for further analysis. To calculate the changes of FR after 24 h incubation of statins, the FR-values of the incubated cells were normalized by dividing them through the average FR value of all control cells of the respective experimental cycle resulting in FR n .
In order to test the effect of acute application of statins, cells were incubated with Fura-2-AM as described above 1–2 days after seeding. Cells were superfused with control solution for 1 min in the experimental setup. Subsequently, histamine was applied up to three times at concentrations of 1–50 μM followed by a washout with control solution for 1–2 min. Statins were applied in concentrations of 50 and 100 μM to resting cells as well as during stimulation with 10 μM histamine.
All experiments were performed at room temperature between 20 and 23°C. Means ± SEM (n = number of cells) were calculated from pooled FR n . Statistical significance was tested by means of the two-sided Student's t-test.
The long-term effect of statins on the resting intracellular calcium concentration was measured by preincubation of HUVEC cells for 24 h with the respective statins. Since the resting [Ca2+]i levels varied from batch to batch, we expressed the statin effects as FR n , i.e. always normalized the fluorescence ratio to the values obtained from non-treated control cells. For 10 μM cerivastatin the FR n value was 1.104 ± 0.0103 (n = 72, P < 0.01). This means that statin incubation increased FR, which is a direct measure for an increase of the intracellular free calcium concentration, by 10.4%. 5 μM cerivastatin also increased FR n to 1.104 ± 0.0237 (n = 17) and 1 μM cerivastatin to 1.08 ± 0.0113 (n = 29). For 0.1 μM cerivastatin FR n was 1.01 ± 0.0122 (n = 30) which was not significantly increased (P = 0.29). Incubation with 10 μM fluvastatin increased FR n to 1.117 ± 0.0263 (n = 25, P < 0.01).
Thus, as summarized in Fig. 1, cerivastatin and fluvastatin significantly increased the fluorescence ratio under resting conditions.
The dependency of statin induced [Ca2+]i increase on the driving force for Ca2+ was tested by application of extracellular solution containing 10 mM CaCl2. Application of the 10 mM CaCl2 solution up to 4 min did not change the resting calcium concentration of the cerivastatin treated cells (10 μM, 24 h). Application of nominally Ca2+ free solution over up to 3 min did not change the resting [Ca2+]i either.
To investigate whether the increase of [Ca2+]i after statin incubation is specific to endothelial cells, we repeated the protocol with SH-SY5Y human neuroblastoma cells. Incubation with 10 μM cerivastatin did not lead to a significant change in FR n (0.972 ± 0.0106, n = 23, P = 0.14).
Although endothelial cells do not express G kinase, Volk et al. have observed an NO-induced transient increase of [Ca2+]i . To check whether the increase of [Ca2+]i after incubation with statins was caused by an increase of NO due to a direct activation of eNOS by statins, we tested the effect of cerivastatin in the presence of L-NAME, an inhibitor of eNOS. L-NAME alone had no effect on FR n . As shown in Fig. 1, 10 μM Cerivastatin increased FR n also in the presence of 50 μM L-NAME. Thus, we conclude that the observed effect of the statins on the resting calcium concentration is not a phenomenon common to all cells. In addition, it is not mediated by an direct (Ca2+-independent) effect of the statins on NO.
After 24 h incubation with one of the statins (or control group without statin) cells were stimulated with 10 μM histamine. Almost all cells have shown a typical increase of [Ca2+]i (like those shown in Fig. 2). There was no obvious difference in the stimulated calcium transient pattern between the statin group and control group. Because of the large intercellular variability of the quantitative calcium response it was impossible to apply statistics for comparison between groups.
We further examined the effect of acute statin application to HUVEC cells on the resting [Ca2+]i level as well as on histamine-induced Ca2+ release. Cerivastatin or fluvastatin at concentrations between 50 and 100 μM were directly applied to the cells. In the absence of agonist, application of the statins for 1 to 5 min did not result in an effect on resting levels of [Ca2+]i. In Fig. 2A such control applications are shown for fluvastatin.
The putative influence of statins on agonist-induced transients of [Ca2+]i was tested with various protocols. As a control, a first Ca2+ transient was elicited with histamine only. The subsequent Ca2+ transient, again elicited with histamine, was then measured during simultaneous (Fig. 2B) or preceded statin application (Fig. 2C). In another series of experiments, statins were applied after the initial increase of [Ca2+]i responding to the application of histamine, in order to test whether statins might primarily affect the return of [Ca2+]i to basal levels. In none of these experiments histamine-induced Ca2+ signals in HUVEC cells were significantly altered by statins.
There is ample of evidence for so-called pleiotropic effects of statins – beneficial and vasoprotective effects which are independent on the lipid-lowering properties of these substances. Various authors have shown that statins are capable of modulating the flow properties of blood vessels. In vivo studies have shown after a short period of statin administration to humans a significantly increased blood flow under resting conditions and after stimulation .
The underlying mechanism for this phenomenon is not completely understood. The results of Alvarez de Sotomayor et al. suggest that the improved vasodilatation is mainly mediated by an endothelium dependent relaxation which is induced by an increased production of nitric oxide . An up-regulation of eNOS apparently plays an important role for this process [3, 10]. However, not only an up-regulation of eNOS expression may be responsible for a statin-induced increase of blood flow. Also the direct activation of eNOS is likely to contribute to endothelium dependent relaxation .
Beside the activation of eNOS by mechanic stress, the calcium-calmodulin dependent activation of the enzyme in association with receptor-dependent and -independent agonists is the main pathway for the activation of eNOS; in contrast to iNOS, the activity of eNOS tightly correlates with [Ca2+]i [4, 5].
The concentration of free Ca2+ in the cytosol is extremly low, whereas the concentration in the extracelluar space and in the endoplasmatic reticulum is high. When a signaling molecule like Histamin binds to a G-protein-linked receptor, phospholipase C-β becames activated. This enzyme generates two products: inositol triphosphate (IP3) and diacylglycerol. IP3 binds to IP3-gated Ca2+-release channels in the ER membrane. Ca2+ rushes into the cytosol, dramatically increasing the local Ca2+ concentration and triggering Ca2+-responsive proteins in the cells like eNOS: Ca2+ binds to Calmodulin, a specific Ca2+ binding protein. It undergoes a conformational change when it binds Ca2+, but it has no encyme activity itself. It acts by binding to other proteins and therby altering their activity. In this way it activates eNOS. It is well documented that IP3-mediated Ca2+ release is also controlled by cytoplasmatic Ca2+ concentration . Small increases in calcium concentration around 100–300 nm enhance the activity of the IP3 receptor dramatically.
With the presented experimental results we have shown a small but significant increase in resting levels of [Ca2+]i induced by treatment with cerivastatin and fluvastatin. This small increase of [Ca2+]i possibly represents a major contribution to the enhancement of endothelium derived relaxation of blood vessels in vivo and in vitro, since allosteric regulation of eNOS by calcium-calmodulin and the modulation of IP3 receptor activity by intracellular calcium can multiply this effect.
It is difficult to compare an endothelium cell under resting conditions with an endothelium cell in an intact blood vessel under normal flow conditions. However, our results are in accordance with the investigation of O'Driscoll et al. that indicates that L-NAME-mediated vasoconstriction is enhanced after treatment with statins, indicative of an augmented basal effect of NO .
After 24 h incubation with statins we could not observe obvious changes of histamine-induced Ca2+ transients. Because of a broad intercellular variety of histamine-induced Ca2+ transients, a quantitative comparison between groups was not feasible. Furthermore, direct comparison of the Ca2+ response to histamine for one cell before and after incubation with statins was technically not possible.
We did not find any acute effect of statin treatment on [Ca2+]i. This result is in accordance with the described in vivo results. Because of the broad intercellular variety in agonist-induced Ca2+ signals in HUVEC cells and the long lasting statin incubation it will not be feasible to perform experiments on single cells to explore the role of the intracellular calcium stores and calcium pumps for the observed effects.
One possible pathway leading to the increase in [Ca2+]i after incubation with statins could be via an increase of NO by means of direct eNOS activation by statins . To exclude this hypothesis we compared cells incubated with 10 μM cerivastatin alone and cells incubated with 10 μM cerivastatin and 50 μM L-NAME as an inhibitor for the eNOS. In contrast to other L-Arginine inhibitors like L-NMMA, L-NAME has a different selectivity to the three NOS isoforms. The selectivity iNOS / eNOS is reported with 0,05 and the pIC50 with 5,82 for human isoencymes . So, L-NAME is not highly active for eNOS inhibition, but for the applied concentration of 50 μM in HUVEC we expected a satisfied and selective inhibition of eNOS.
Because there was no significant difference of the changes of the on [Ca2+]i caused by cerivastation with or without L-NAME, we conclude that the observed effects of statins on [Ca2+]i are not indirectly mediated by NO.
Incubation of the cells for 24 h with cerivastatin or fluvastatin significantly increased the resting [Ca2+]i. Increase of resting [Ca2+]i in the presence of cerivastatin also occurred when the nitric oxide synthase was inhibited. Transient Ca2+ release induced by histamine was not affected. Recently published results of Mizuno et al. have shown that there is a clearly quantitative relationship between the concentration of [Ca2+]i and NO production . The relationship between the integrated [Ca2+]i and NO production was described by a straight line. This encourages us in the assumption that the observed changes of [Ca2+]i through statins could be one possible mechanism for the improvement of endothelial function after treatment with these substances in vessels challenged by arteriosclerosis.
endothelial nitric oxide synthase
human umbilical vein endothelial cell
- [Ca2+]i :
intracellular free calcium concentration
3-hydroxy-3-methylglutaryl coenzyme A
Alvarez de Sotomayor M, Herrera MD, Marhuenda E, Andriantsitohaina R: Characterization of endothelial factors involved in the vasodilatory effect of simvastatin in aorta and small mesenteric artery of the rat. Br J Pharmacol. 2000, 131: 1179-1187.
Boer R, Ulrich WR, Klein T, Mirau B, Haas S, Baur I: The inhibitory potency and selectivity of arginine substrate site nitric-oxide synthase inhibitors is solely determined by their affinity toward the different isoenzymes. Mol Pharmacol. 2000, 58 (5): 1026-34.
Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA, Liao JK: Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA. 1998, 95: 8880-8885. 10.1073/pnas.95.15.8880.
Fleming I, Busse R: Signal transduction of eNOS activation. Cardiovasc Res. 1999, 43: 532-541. 10.1016/S0008-6363(99)00094-2.
Govers R, Rabelink TJ: Cellular regulation of endothelial nitric oxide synthase. Am J Physiol Renal Physiol. 2001, 280: F193-206.
Grynkiewicz G, Poenie M, Tsien RY: A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem. 1985, 260: 3440-3450.
Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, Sanchez-Pascuala R, Hernandez G, Diaz C, Lamas S: Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest. 1998, 101: 2711-2719.
Kaesemeyer WH, Caldwell RB, Huang J, Caldwell RW: Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. Am Coll Cardiol. 1999, 33: 234-241. 10.1016/S0735-1097(98)00514-2.
Laufs U, la Fata V, Plutzky J, Liao JK: Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998, 97: 1129-1135.
Laufs U, Liao JK: Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem. 1998, 273: 24266-24271. 10.1074/jbc.273.37.24266.
Mak DO, McBride S, Foskett JK: Inositol 1,4,5-trisphosphate activation of inositol trisphosphate receptor Ca2+ channel by ligand tuning of Ca2+ inhibition. Proc Natl Acad Sci U S A. 1999, 95 (26): 15821-5. 10.1073/pnas.95.26.15821.
Mizuno O, Kobayashi S, Hirano K, Nishimura J, Kubo C, Kanaide H: Stimulus-specific alteration of the relationship between cytosolic Ca2+ transients and nitric oxide production in endothelial cells ex vivo. Br J Pharmacol. 2000, 130: 1140-1146.
Muck W: Clinical pharmacokinetics of Cerivastatin. Clin Pharmacokinet. 2000, 39: 99-116.
O'Driscoll G, Green D, Taylor RR: Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation. 1997, 95: 1126-1131.
Sacks FM, Pfeffer MA, Moye LA: The effect of Pravastatin on coronary events after myocardial infarction in patient with average cholesterol levels. N Engl J Med. 1996, 335: 1001-1009. 10.1056/NEJM199610033351401.
Shepherd J, Cobbe SM, Ford I: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West Of Scotland Coronary Study Group. N Engl J Med. 1995, 333: 1301-1307. 10.1056/NEJM199511163332001.
Volk T, Mading K, Hensel M, Kox WJ: Nitric oxide induces transient Ca2+ changes in endothelial cells independent of cGMP. J Cell Physiol. 1997, 172: 296-305. 10.1002/(SICI)1097-4652(199709)172:3<296::AID-JCP3>3.0.CO;2-J.
Wagner AH, Kohler T, Ruckschloss U, Just I, Hecker M: Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol. 2000, 20: 61-69.
Yamada M, Huang Z, Dalkara T, Endres M, Laufs U, Waeber C, Huang PL, Liao JK, Moskowitz MA: Endothelial nitric oxide synthase-dependent cerebral blood flow augmentation by L-arginine after chronic statin treatment. J Cereb Blood Flow Metab. 2000, 20: 709-717.
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2261/4/4/prepub
We thank Angela Roßner for the excellent cell culture and Novartis AG and Bayer AG for supporting this study.
SH participated in the design of the study, carried out the cell experiments, performed the statistical analysisand drafted the manuscript.
GS participated in the cell experiments and drafted the manuscript.
HRF participated in the design and coordination of the study.
SHH participated in the design and coordination of the study.
All authors read and approved the final manuscript.